Who
Hubert C. Chen
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Viking Therapeutics; Officer, Forte Biosciences; Chief Medical Officer, Metacrine; Chief Medical Officer, Pfenex.
In numbers
- Trades disclosed
- 24
- Buys
- 1
- Sells
- 0
- Bought
- $12K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 1 Dec 2014
- Last trade
- 1 Jun 2026
- Last filed
- 3 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jun 2026filed 3 Jun 2026 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —190,000 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —190,000 at $0.00 | filing |
| 1 Jan 2024filed 3 Jan 2024 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 1 Jan 2024filed 3 Jan 2024 | Forte BiosciencesBiotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 1 Jan 2024filed 3 Jan 2024 | Forte BiosciencesBiotechnology | SEC FORM 4 Code F | $2,5203,073 at $0.82 | filing |
| 1 Oct 2023filed 3 Oct 2023 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 1 Oct 2023filed 3 Oct 2023 | Forte BiosciencesBiotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 1 Oct 2023filed 3 Oct 2023 | Forte BiosciencesBiotechnology | SEC FORM 4 Code F | $1,7112,593 at $0.66 | filing |
| 31 Jul 2023filed 2 Aug 2023 | Forte BiosciencesBiotechnology | SEC FORM 4 Code A | $75K74,257 at $1.01 | filing |
| 1 Jul 2023filed 5 Jul 2023 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 1 Jul 2023filed 5 Jul 2023 | Forte BiosciencesBiotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 1 Jul 2023filed 5 Jul 2023 | Forte BiosciencesBiotechnology | SEC FORM 4 Code F | $2,6972,593 at $1.04 | filing |
| 1 Apr 2023filed 4 Apr 2023 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 1 Apr 2023filed 4 Apr 2023 | Forte BiosciencesBiotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 1 Apr 2023filed 4 Apr 2023 | Forte BiosciencesBiotechnology | SEC FORM 4 Code F | $2,6192,593 at $1.01 | filing |
| 25 Feb 2023filed 27 Feb 2023 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 7 Jun 2022filed 8 Jun 2022 | Forte Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 20 May 2021filed 20 May 2021 | Metacrine | SEC FORM 4 Bought | $12K3,289 at $3.60 | filing |
| 10 Feb 2021filed 12 Feb 2021 | Metacrineoption or derivative | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 1 Feb 2018filed 2 Feb 2018 | Pfenexoption or derivative | SEC FORM 4 Code A | —78,407 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.